arrow_back Search

HOUSE_OVERSIGHT_025888

House Oversight Committee
insert_drive_file IMAGES-008-HOUSE_OVERSIGHT_025888.txt description DOCUMENT text_fields 265 words · 1.6k chars

From: Sultan Bin Sulayern

Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [jeevacation@gmail.com] Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today

Importance: — High

Have you heard of this colestrol

Jul 24, 2015 @ 3:23 PM 1,169 views

The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot

Matthew Herper , Forbes Staff

I cover science and medicine, and believe this is biology's century.

® Follow on Forbes

(1970)

e Full Bio e Recent Posts ° Popular Posts

I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page.

Loading...

Loading...

The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins.

It might be a big step in the battle against heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line.

“Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol,” says Steven

HOUSE_OVERSIGHT_025888